IONS News and Press, Ionis Pharmaceuticals Inc. From 01/22/24

2024-01-22 14:00:02 ET William Blair analyst issues OUTPERFORM recommendation for IONS on January 22, 2024 02:35PM ET. The previous analyst recommendation was Outperform. IONS was trading at $51.455 at issue of the analyst recommendation. The overall analyst consensus : ...

2024-01-22 08:00:31 ET More on Ionis Pharmaceuticals Ionis Pharmaceuticals: Pioneering Precision Medicine Ionis Pharmaceuticals, Inc. (IONS) Q3 2023 Earnings Call Transcript Ionis Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation FDA approv...

Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema PR Newswire Donidalorsen met the primary endpoint with a statistically significant reduction in the rate of HAE attacks in patients tr...

2024-01-18 21:08:20 ET Summary ARK Invest's 13F portfolio value increased by 29% this quarter, reaching approximately $16.89 billion. The top three holdings in the portfolio are Coinbase Global, UiPath, and Tesla. ARK Invest made new stakes in ProShares Bitcoin Strategy ETF an...

2024-01-18 12:45:02 ET Piper Sandler analyst issues BUY recommendation for IONS on January 18, 2024 01:00PM ET. The previous analyst recommendation was Buy. IONS was trading at $50.75 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curren...

2024-01-16 11:49:56 ET More on iShares Russell 1000 Growth ETF: IWF: Price Isn't Everything; Favor Growth Over Value Citi’s 30 stocks for its 2024 top themes Top overweight stocks with high growth and low volume - MS Seeking Alpha’s Quant Rating...

Positive preliminary analysis of 15 mg cohort in the PRAX-628 study in epilepsy patients with Photo-Paroxysmal Response (PPR) exceeds expectations; topline results expected in 1Q 2024 after completion of 45 mg cohort Enrollment for both ulixacaltamide Phase 3 Studies in the Essential3...

Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases PR Newswire – Numerous value-driving commercial, regulatory and pipeline milestones anticipated – ...

2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...

2024-01-02 16:14:13 ET More on Ionis Pharmaceuticals Ionis Pharmaceuticals: Pioneering Precision Medicine Ionis Pharmaceuticals, Inc. (IONS) Q3 2023 Earnings Call Transcript Ionis Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation FDA approv...